New FDA-Approved Oral Treatment Advances ESR1 Mutation Breast Cancer Care

Buzzline

The FDA has authorized an oral combination therapy of Inluriyo and Verzenio for adults with ER-positive, HER2-negative breast cancer featuring ESR1 mutations who progressed after hormone therapy. Trials indicate this regimen significantly extends progression-free survival over Inluriyo alone.

Transcript

00:00A new oral pill combination doubles the time before breast cancer spreads in patients with

00:05a specific mutation. The Food and Drug Administration approved Eli Lilly's Inlurio

00:10and Verzenio for adults with ER positive. HER2 negative advanced breast cancer carrying an ESR1

00:16mutation. In a trial of 159 patients, those taking both drugs went a median of 11.1 months

00:23before their cancer progressed. Compared with 5.5 months for those on Inlurio alone,

00:28this combo blocks estrogen signals and slows cancer cell growth. Offering a new option after

00:34hormone therapy stops working, doctors can identify eligible patients with a blood test for the ESR1

00:40mutation. Side effects include diarrhea in 86% of patients, but only 6% stopped treatment due to

00:47side effects. This approval marks a shift toward combining targeted therapies for better control

00:52of resistant breast cancer. Disclosure. This video contains stock footage and content created or

00:58enhanced using AI assisted tools.

Category

Transcript

Recommended